Bring clarity
to brain injury.
ProbTBI™ is a non-invasive, point-of-care test that detects concussion and traumatic brain injury from a single body-fluid sample — read in minutes, as simply as a pregnancy test.
Brain injury is still hard to measure.
TBI diagnosis and treatment are unmet needs in medicine — today there is no non-invasive, power-free, point-of-care tool to assess the extent and severity of a traumatic brain injury. Nearly 5 million US emergency visits each year involve head injury, and up to 90% are mild TBI, many undiagnosed.
From injury to answer.
No imaging, no central lab, no specialist. ProbTBI brings an objective biomarker result to wherever the injury happens.
A lab result, at the point of injury.
No imaging. No central lab. No waiting. ProbTBI puts an objective, biomarker-based answer in the hands of first responders, emergency teams, sports physicians and GPs.
Non-invasive sample
Body-fluid sample — comfortable for adults and children alike.
Result in minutes
Point-of-care read at the bedside or on the sideline.
Simple to interpret
Positive or negative — no training, no instrument required.
Built on IP
Protected by a portfolio of 7 patents. Medicortex name trademarked.
As easy to interpret as a pregnancy test — positive or negative, no instrument required.
Evaluated across three hospital studies.
Adult mild TBI
Biomarker presence, TBI specificity and time-course after injury across Finnish central hospitals.
Extended detection
Accelerated recruitment at Turku University Hospital; comparison to orthopedic and healthy controls.
Children & adolescents
Large paediatric cohort with suspected mild TBI — validating the test in young patients.
We have the opportunity to develop a portable, non-invasive test for quick detection of mild TBI and concussion — and thereby help patients and families who so desperately need it.
How is the sample collected?
How do I read the result?
Where is Medicortex based?
What is the listing status?
Board, management & ownership.
MSc (Uppsala) and MBA (IMD Lausanne); 30+ years of leadership in pharmaceutical, medical-device and medical-aesthetics companies, with global CEO and chairman roles, and exits at Medicis, J&J and Galderma.
PhD in Neurobiology (Weizmann Institute) and MBA (University of Haifa); deep drug-development, GMP and manufacturing experience. Former CEO of BrainStorm Cell Therapeutics (NASDAQ: BCLI) and of ProNeuron.
30+ years in leadership across foundations and companies in the Turku region, with expertise in sales management, networks, investing and fundraising.
Globally networked drug- and business-development professional; currently Chief Commercial Officer at CRST Oy and a certified board member.
MSc in Economics (International Business), European Business School London; experienced business controller and CFO and a certified board member for listed companies. Serves as the group's operational CFO.
Founder; a track record leading early-stage biotechnology companies through R&D and GMP.
MSc in Economics (International Business), European Business School London; long experience as business controller and CFO. Board member and the group's operational CFO.
PhD in Molecular Biotechnology & Diagnostics; Head of R&D since 2015, leading assay development and detection R&D.
MSc in Human Neuroscience (Turku); oversees operations including procurement, supplier relations, HR and public relations.
Aligned for the long term.
The founder and board hold a significant stake, aligning leadership with shareholder value. The full register is maintained at Euroclear.
The listed vehicle's existing holdings.
Medicortex International AB (publ) — formerly NOSIUM AB (publ) — carries a portfolio of holdings from its venture-builder history. Combined book value ≈ 14.4 MSEK. Figures per company filings.
Investment company investing in smaller, listed Nordic growth companies.
Latest from Medicortex.
Reverse takeover completed — Adrian Harel appointed CEO
The acquisition of Medicortex Finland is complete, NGM's conditions are satisfied, and NOSIUM AB (publ) is renamed Medicortex International AB (publ).
Read moreMedicortex's new article published
A new peer-reviewed article on ischemic stroke biomarkers is now available.
Read moreMedicortex name now trademarked
The Medicortex name is now a registered trademark; ProbTBI™ has been trademarked for years.
Read moreLetter from the Chairman
An update to shareholders on the listing, strategy and the road ahead.
Read moreInvest in the clarity patients deserve.
Medicortex International AB (publ) completed its reverse takeover on 30 June 2026 and trades on NGM Growth Market under MEDFIN. The group has raised EUR 8.4M, including three US Department of Defense grants, holds 7 patents, and is advancing ProbTBI toward a TBI-diagnostics market forecast at USD 3.3bn by 2029. Certified Adviser: Nordic Certified Adviser AB.